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early-stage endometrial cancer?Many patients with endometrial cancer are diagnosed in their
early stage, and the majority of them are found to belong to less
invasive cell types [Grades 1 and 2, as well as Type I (endometrioid
cell type)] [1]; all of which contribute to excellent outcome for
these patients [2]. The excellent outcome is dependent on the ﬁnal
surgical and pathological ﬁndings, which include a small volume of
tumor, tumor limited to the uterus with absent or superﬁcial myo-
metrium invasion and absent lympho-vascular space invasion and
no cervical involvement, belonging to Grade 1 or 2 endometrioid-
cell-type endometrial cancer, and, of most importance, free of
extrauterine spreading [3,4]. To obtain the aforementioned ﬁnal
surgico-pathological features, a thorough and complete staging
surgery, mainly containing cytology, total hysterectomy, bilateral
salpingo-oophorectomy, bilateral pelvic lymph-node dissection,
para-aortic lymph-node dissection, and possible multiple random
biopsies during operation, should be performed [3]. That is to say,
the belief of excellent outcome for these patients might be much
more acceptable in those womenwho have undergone a “thorough
and complete staging surgery,” and their ﬁnal surgico-pathological
stage of the endometrial cancer is limited to International Federa-
tion of Gynecology and Obstetrics Stage IA, Grade 1 or Grade 2,
and endometrioid cell type [4].
A recent paper has been published in the Taiwanese Journal of
Obstetrics & Gynecology last year [5]. This study might challenge
the necessity of a thorough and complete staging surgery for endo-
metrial cancer. In Lau et al’s paper [5], 64 patients who did not
receive a thorough and complete stating surgery were analyzed.
Specially, all patients did not have the standard bilateral salpingo-
oophorectomy. The results showed that these patients had an
excellent prognosis with almost 100% survival rate (98.3% of the
5-year recurrence-free survival rate during a median follow-up
period of 44.6 months) [5]. Therefore, the authors concluded that
preservation of the ovaries does not increase the disease-related
mortality, and further highlighted that a more conservative
approach to surgical staging may be considered in premenopausal
womenwith early-stage endometrial cancer without risk factors. In
fact, Dr. Lau has published one paper based on the one of the largest
medical centers in North Taiwan in 2014, and found that there were
no statistically signiﬁcant differences of disease-free survival be-
tween Stage I patients with and without oophorectomy (hazard
ratio ¼ 2.72, 95% conﬁdence interval ¼ 0.48e15.59), contributing
the conclusion theymade that ovarian preservationmight be a sug-
gestion for the premenopausal women with early-stage low-risk
endometrial cancer [6].http://dx.doi.org/10.1016/j.tjog.2015.12.002
1028-4559/Copyright © 2016, Taiwan Association of Obstetrics & Gynecology. Published b
(http://creativecommons.org/licenses/by-nc-nd/4.0/).This study, a multicenter retrospective study, was conducted by
the Taiwanese Gynecologic Oncology Group (TGOG), and might be
a good representative of the “real” situation of patients and pro-
vides useful information in the management of womenwith endo-
metrial cancer, especially for those women with postoperatively
accidental ﬁndings of “supposed” early-stage endometrial cancer.
However, it is questionable that this suggestion could be accepted
by the patients and/or the physicians. In fact, there are many uncer-
tainties for the conclusion the authors made. First, although many
strategies could be applied for women with endometrial cancers
who want to maintain future fertility, a follow-up period was short
and the results seemed to be “acceptable”. However, nearly all pa-
pers available still highly commented that total hysterectomy
should be made after completing the births. In both publications
by Dr. Lau [5,6], the authors did not focus on this part, and by
contrast, they focused on the possibility of preservation of the
ovary, which is themain source of the female sex hormone, contrib-
uting to maintain the general health of women, including a healthy
cardiovascular system [7] and bone strength [8].
The discussion of the ovarian preservation inwomenwith endo-
metrial cancer, especially for those premenopausal women, can be
found elsewhere [4]. The reasons for favoring preservation of the
ovary include the following: (1) it is extremely low risk for
cancer-related morbidity and mortality, such as an extremely low
incidence of extrauterine spreading (occult ovarian metastases),
and a similar 5-year disease-free survival or overall survival be-
tween patients with and without ovarian preservation; and (2) it
is beneﬁcial for the presence of the female sexual hormone for
the general health of premenopausal women. By contrast, the rea-
sons against the preservation of the ovary include the following: (1)
high possibility of synchronous ovarian cancer with endometrial
cancer; and (2) endometrial cancer is a female sex-hormone-
dependent disease. Therefore, preservation of the ovary in women
with endometrial cancer during operation, especially for young
women and “supposed” early-stage endometrial-cancer patients,
might not be a standard therapy.
Finally, it is still uncertain that patients with endometrial cancer
could be managed by incomplete staging surgery. In addition, it is
also controversial that the postoperative adjuvant therapy,
including radiotherapy and/or chemotherapy for these women
with endometrial cancer, could play a rescue method in place of a
thorough and complete staging surgery. According to the results
of the TGOG, the answer to the ﬁrst question might be acceptable,
because among 64 patients, 50 patients did not have data abouty Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license
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able, because one-eighth of the patients received postoperative
adjuvant therapy, and the outcome seemed to be excellent in the
current TGOG study [5]; the role of postoperative adjuvant therapy
for these supposed early-stage endometrial-cancer patients is still
being argued. It raised the following question: “is it really accept-
able by the majority of gynecological oncologists?” We are afraid
that none could respond to it. We are happy to learn the readers'
interest [9], and also encourage that the principal investigators of
the TGOG study share their opinions on this [10]. Any ﬁnding by
a study should be carefully evaluated, and if it is to change our daily
practice, much more evidence is required.
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